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 College oAbstract Background: The novel urinary neutrophil gelatinase-associated lipocalin (uNGAL) is
an early and highly predictive biomarker that is rapidly released in acute kidney injury (AKI).
Objective: We investigated the early expression of uNGAL (ﬁrst 4 days after injury) as a predic-
tor of acute kidney injury complicating circulatory shock.
Methods: Urinary-NGAL level was measured in collected urine samples of 45 patients (pts) with
circulatory shock, during the ﬁrst 6 h and after 24 h of onset of shock. Eleven patients responded to
ﬂuid infusion ± vasopressors and were considered as a control group.
Results: The estimated uNGAL at day 1 and day 2, could predict AKI presenting at days 2, 3
and 4 (P< 0.05, <0.001 and <0.001, <0.001), respectively. Apart from all conventional kidney
parameters and biomarkers, signiﬁcant inverse correlations could be detected only between uNGAL
at days 1 and 2 with the corresponding urine output in the patients’ group (r= 0.41 and 0.64,
P< 0.05 and <0.001, respectively). The best cutoff value of uNGAL at day 1 was 26 ng/mL, withhil gelatinase-associated lipo-
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80 M. Fouda et al.sensitivity and speciﬁcity of (62% and 69%) and (75% and 80%), for prediction of AKI presented
at days 2 and 3, respectively. While the best cutoff at day 2 was 29 ng/mL, with sensitivity and spec-
iﬁcity of (70% and 74%) and (90% and 80%) for prediction of AKI diagnosed at days 3 and 4,
respectively. Urinary-NGAL at days 1 and 2 could signiﬁcantly predict mortality complicating
AKI only at day 2 (area under curves were 0.65 and 0.86, and P< 0.05 and <0.001, respectively).
Conclusions: Urinary-NGAL seems to be a potential early and sensitive biomarker for AKI
complicating circulatory shock. Its persistent increased level at day 2 also can predict mortality
complicating AKI in those patients.
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Acute kidney injury (AKI) is a common complication within
critically ill patients, affecting about 25% of all intensive care
unit (ICU) admissions. Among these patients, circulatory
shock is thought to be the most common contributing factor
to AKI and is associated with high mortality rates of 40–
50% [1,2].
Interestingly, the mortality from AKI complicating circula-
tory shock has not changed markedly over the years, mainly
because of the late diagnosis, lack of sensitivity and speciﬁcity
of the current AKI biomarkers and the lack of effectiveness of
the new therapies [2–5].
Currently, AKI is routinely diagnosed and followed up by
measuring serum creatinine concentration. Although it has
been widely used for the assessment of glomerular ﬁltration
rate (GFR), it has poor sensitivity and speciﬁcity in AKI, as
it lags behind both renal injury and renal recovery [6]. It does
not directly reﬂect the kidney cell injury, but rather the delayed
functional consequences of the damage after >50% loss of the
kidney function [7,8]. So, an early detection of adult patients
with kidney injury would provide an opportunity to treat
and prevent the extension of kidney injury before the serum
creatinine rises [9].
Recent studies have proposed many biomarkers for the
early detection of AKI, which may facilitate earlier diagnosis
and proper management resulting in fewer complications and
improved outcomes [10,11].
Neutrophil gelatinase-associated lipocalin (NGAL) appears
to be the most promising of all biomarkers [11]. NGAL was
originally puriﬁed as a 25 kDa protein covalently bound to gel-
atinase from neutrophils which is normally expressed at very
low levels in several human tissues, including the kidneys,
lungs, stomach, and colon [12,13]. NGAL protein is also rap-
idly and massively induced in kidney tubule cells soon after re-
nal ischemia [14].
Urinary-NGAL (uNGAL) is probably more reﬂective than
plasma-NGAL for evaluation of the local renal injury [15]. It
rapidly accumulates within hours in the kidney tubules and ur-
ine after nephrotoxic or ischemic insults [16], and represents an
early predictive biomarker for the development of AKI 1–
3 days earlier than the serum creatinine [10]. In contrast to
the plasma-NGAL, uNGAL is not elevated in septic patients
without AKI [17].
Based on the available studies, the use of uNGAL as a mar-
ker of septic AKI is promising but requires further investiga-
tion. In particular, the relationship between uNGAL
expression, plasma-NGAL and renal inﬂammation requiresadditional clariﬁcation. However, few studies have speciﬁcally
addressed the issue of expression of uNGAL in renal tissues
during sepsis, but never in circulatory shock.
The purpose of this study is to investigate the pattern of
uNGAL level in AKI as an early diagnostic and prognostic
biomarker and to explore the relationship with the other con-
ventional renal biomarkers, in patients with circulatory shock.
Materials and methods
This study was conducted on 45 Egyptian patients admitted to
ICU of the Department of Critical Care Medicine, Cairo Uni-
versity Hospitals, Al Haram hospital (Ministry of Health Hos-
pital) and Al Salam hospital (private hospital), from October
2010 to May 2011 with circulatory shock. All patients were en-
rolled in the study and followed up, only during their stay in
ICU.
This study was approved by the Ethics Committee Review
Board of the Faculty of Medicine, Cairo University. Informed
written consent was acquired from each patient before the
enrollment in the study.
Thirty-four patients (19 males) did not show any response
to ﬂuid ± vasopressor therapy and were considered as the pa-
tients’ group, and 11 patients (8 males) showed an early re-
sponse to ﬂuid ± vasopressor therapy and were considered
as the control group; mean age: 45.6 ± 17.4 (15–75) years
for the patients and 48.5 ± 14.2 (26–69) years for the controls,
P=NS.
All subjects were enrolled in the study within 6 h from the
diagnosis of circulatory shock with normal kidney functions,
and followed up consecutively for 4 days during their stay in
ICU.
Inclusion criteria
Patients presented with circulatory shock during their ICU
stay; diagnosed on the basis of the Empiric Criteria of Circu-
latory Shock [18], which requires 4 out of the following:
1) Ill Appearing or altered mental status.
2) Heart rate >100 beat/min.
3) Respiratory rate >22/min, or paCO2 <32 mmHg.
4) Arterial hypotension (systolic blood pressure
690 mmHg or mean arterial blood pressure
670 mmHg), for >20 min duration.
5) Urine output <0.5 mL/kg/h.
6) Arterial base deﬁcit <5 mEq/L.
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1) Preexisting renal insufﬁciency; baseline serum creatinine
>2 mg/dl on enrollment.
2) Current use of known nephrotoxic drugs.
3) Severe urinary tract infection; diagnosed by the presence
of pyuria >50 pus cells/HPF.
4) Post renal transplantation surgery.
5) Known cases of polycystic kidney, lupus nephritis or
IgA nephropathy.
6) Known cases of adenocarcinoma.
7) Any old history of renal disease.
All patients were subjected to:
(1) Full clinical evaluation including the medical history
and the clinical examination.
(2) Routine Laboratory Investigation; including blood
urea and serum creatinine, arterial blood gases
(ABG), complete blood count (CBC) and urine
analysis.
(3) Abdominal ultrasonography was done once, to rule out
any old kidney disease.
(4) Mayo Quadratic formula (for patients with preserved
kidney function) was used to estimate the glomerular ﬁl-
tration rate (GFR) [19]:
GFR= [1.911 + 5.249/serum creatinine (SCr)  2.14/
SCr2  0.00686 · Age (years)  0.205 (if female)] (If SCr
<0.8 mg/dl, use 0.8 for SCr).
(1) Acute kidney injury (AKI) staging was done using the
acute kidney injury network criteria (AKIN) [20]
(Table 1):
(2) Detection of uNGAL using ELISA at day 1 (during the
ﬁrst 6 h of the patient enrollment):
Urine samples were aseptically collected and voided directly
into a sterile container. Centrifugation of the urine samples at
1000· for 15 min is performed to remove the particulate matter
and the supernatant then the aliquot stored at 20 C. Re-
peated freeze–thaw cycles were avoided which may cause erro-
neous results [12]. Urinary-NGAL was analyzed by the
commercially available Enzyme Linked Immunosorbent Assay
(ELISA) kits (Biovender Laboratorni Medicina, Czech Repub-
lic) and performed as previously described [21]; brieﬂy, it is a
sandwich monoclonal ELISA procedure determining uNGAL
in human urine. Microtiter plates coated with monoclonal
antibodies against human uNGAL were coated with samples
or standards (uNGAL concentrations ranging from 1 to
1000 lg/L), which were read at 450 nm with a microplate read-
er. All tests were performed according to the manufacturers’
instructions.Table 1 Acute kidney injury network criteria (AKIN).
Stage Serum creatinine criteria
1 › toP1.5· from baseline, or › to 0.3 mg/dl f
2 › to P2· from baseline
3 › toP3.0· from baseline, or 4 mg/dl with acu
RRT (renal replacement therapy) irrespective
Only one criterion (serum creatinine or urine output) should be fulﬁlled(1) For follow up, all patients were subjected to:
Full clinical evaluation every 2 h.
(1) Detection of uNGAL using ELISA at day 2:
Urine samples were obtained to test uNGAL only at day 1
and day 2, as it represents an early predictive biomarker for the
development of AKI 1–3 days earlier than serum creatinine
[10].
(1) Measurement of the routine laboratory investigations;
including blood urea and serum creatinine and estima-
tion of GFR was done at days 2, 3 and 4.
Statistical methodsData were collected and veriﬁed before computerized data entry
using the Statistical Package for Social Sciences (SPSS) version
15.0. The data were summarized using descriptive statistics;
including means ± standard deviations. Statistical differences
between groups were tested using the Chi-square test for quali-
tative variables, the independent sample t-test and the one-way
ANOVA (analysis of variance) with the Bonferroni post hoc
test for quantitative normally distributed variables, while the
nonparametricMann–Whitney test and theKruskal–Wallis test
were used for quantitative variables which are not normally dis-
tributed. Spearman’s correlation was done to test for linear rela-
tions between variables. Recessive-Operating Characteristic
Curve (ROC) was used to test for the efﬁciency of uNGAL in
predicting acute kidney injury and mortality. P-values 60.05
were considered statistically signiﬁcant while 60.001 were con-
sidered highly statistically signiﬁcant. Tests of performance
were evaluated by measurement of sensitivity, speciﬁcity, posi-
tive predictive value (PPV), negative predictive value (NPV) and
the diagnostic accuracy.
Results
At day 1, the clinical and biochemistry data of both groups,
were comparable including age, sex, number of diabetics, num-
ber of patients with disturbed conscious level and urine output.
Only, the base deﬁcit showed signiﬁcant lower values in the pa-
tients’ group compared to the controls. Both the ICU stay days
and number of deaths were signiﬁcantly higher in the patients’
group rather than the controls (Table 2).
Compared to the controls, all renal function tests of the pa-
tients showed signiﬁcantly higher values at all days except at
day 1 which showed comparable values to the controls
(Fig. 1). The only exception was uNGAL which showed signif-
icantly higher values at day 1 in the patients’ group compared
to the controls (Table 3).Urine output criteria
rom baseline <0.5 mL/kg/hP 6 h
<0.5 mL/kg/hP 12 h
te ›P0.5 mg/dl, or initiation of
of stage at time of initiation
<0.3 mL/kg/hP 24 h, or
anuriaP12 h
to qualify for a stage.
Table 2 Clinical and routine laboratory results of both groups at day 1.
Patients Controls P value
Diabetes mellitus (number) 14 (41.2%) 6 (54.5%) NS
DCL (number) 34 (100%) 10 (90.9%) NS
Heart rate (beat/min) 110 ± 24 (47–148) 112.3 ± 2 (61–138) NS
MAP (mmHg) 44.9 ± 21.7 (32.3–76.7) 46.3 ± 15.9 (37.4–58) NS
UOP (mL/kg/h) 0.72 ± 0.52 (0–2) 0.82 ± 0.48 (0.2–2) NS
Circulatory shock (number):
Hypovolemic 9 3 NS
Cardiogenic 4 5 NS
Neurogenic 7 4 NS
Septic 7 2 NS
Obstructive 3 1 NS
paCO2 33.4 ± 11.7 (17–74) 35.8 ± 10.4 (22–57) NS
Base deﬁcit (mEq/L) 10.2 ± 9 (29–8.4) 4.2 ± 6 (16–15) <0.05
ICU stay (days) 4.22 ± 2.73 (1–16) 7.85 ± 3.64 (2–21) <0.05
ICU mortality (number) 32 5 <0.001
NS, non signiﬁcant; DCL, disturbed conscious level; MAP, mean arterial blood pressure; UOP, urine output.
Figure 1 Renal function tests: (A) urinary-NGAL, (B) blood urea, (C) serum creatinine and (D) glomerular ﬁltration rate.
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in the patients’ group, with the reduction of the urine outputfrom polyuria to oliguria. On the contrary, no difference was
detected in the control group (Table 4).
Table 3 AKI score on all days.
Patients Controls P value
Day 1 17 (50%) 5 (45.5%) NS
Day 2 33 (97.1%) 4 (36.4%) <0.001
Day 3 31 (96.9%) 1 (10%) <0.001
Day 4 18 (90%) 1 (11.1%) <0.001
NS, non signiﬁcant; uNGAL, urinary neutrophil gelatinase-asso-
ciated lipocalin; GFR, glomerular ﬁltration rate; AKI, acute kidney
injury.
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UOP and uNGAL at both days 1 and 2 (r= 0.41,
P< 0.05, and r= 0.64, P< 0.001, respectively). AKIN-
score showed a signiﬁcant correlation with uNGAL but only
at day 2 (r= 0.46, P< 0.05), otherwise no signiﬁcant correla-
tion could be detected between uNGAL and the other kidney
function tests.
Prediction of acute kidney injury using uNGAL
Urinary-NGAL values at days 1 and 2 to AKIN-score esti-
mated at day 1 showed a bad early prediction of AKI (area un-
der curves were 0.52 and 0.44, P=NS and NS, respectively).Table 4 Effect of urine output on uNGAL level using the one-way
Oliguria <0.3 (mL/kg/h) Average 0.3–1
uNGAL (ng/mL): day 1
Patients 69.4 ± 34.4 (35–135) 57.3 ± 30 (16
Controls – 14.4 ± 9.2 (4.
uNGAL (ng/mL): day 2
Patients 68.9 ± 30.8 (24–130) 55.6 ± 29.2 (2
Controls – 21.5 ± 24.7(3
NS, non signiﬁcant; uNGAL, urinary neutrophil gelatinase-associated lip
Figure 2 (A) ROC curve of uNGAL at days 1 and 2 to AKIN at dayBut for uNGAL values at days 1 and 2 to AKIN-score esti-
mated at day 2, the results showed a good early prediction of
AKI (area under curves were 0.74 and 0.71, P< 0.05 and
<0.05, respectively) (Fig. 2).
Also, uNGAL values at days 1 and 2 to AKIN-score esti-
mated at day 3 showed a good early prediction of AKI (area
under curves were 0.81 and 0.84, P< 0.001 and <0.001,
respectively) (Fig. 2). The same could be detected at days 1
and 2 to AKIN-score estimated at day 4, the results showed
a good early prediction of AKI (area under curves were 0.72
and 0.84, P< 0.001 and <0.001, respectively).
For prediction of AKIN, the best cutoff point at day 1 was
26 ng/mL and at day 2 was 29 ng/mL, respectively (Table 5).
Prediction of mortality complicating acute kidney injury using
uNGAL
Compared to the controls, signiﬁcantly higher mortality rate
could be detected in the patients’ group. Three patients
(8.8%) survived compared to 7 (63.6%) of controls
(P< 0.001). Thirty-one patients (91.2%) died compared to 4
(36.4%) controls (P< 0.001). But the ICU stay in days was
comparable between the patients and the controls; the survi-
vors stayed for 6 ± 2.6 (4–9) days compared to 8.5 ± 6.3
(3–21) days for the controls (P=NS), and those who diedANOVA test.
(mL/kg/h) Polyuria > 1 (mL/kg/h) P value
–120) 34.5 ± 21.5 (19–88) <0.05
1–25) 14.6 ± 14.8 (4–35) NS
7–88) 25.2 ± 18.4 (2.5–55) <0.05
–58) 11.9 ± 9.2 (4–28) NS
ocalin.
2. (B) ROC curve of uNGAL at days 1 and 2 to AKIN at day 3.
Table 6 Prediction mortality using uNGAL in both groups.
uNGAL day 1 uNGAL day 2
Sensitivity 62% 66.7%
Speciﬁcity 70% 100%
PPV 87.5% 100%
NPV 33.3% 52.6%
Diagnostic accuracy 62% 75.6%
Best cutoﬀ value 29 ng/mL 32 ng/mL
uNGAL, urinary neutrophil gelatinase associated lipocalin; PPV,
positive predictive value; NPV, negative predictive value.
Table 5 Prediction of acute kidney injury using uNGAL in both groups.
uNGAL Day 1 uNGAL Day 2
Day 1 Day 2 Day 3 Day 4 Day 2 Day 3 Day 4
Sensitivity 54.5% 62% 68.8% 63.2% 60% 70.4% 73.7%
Speciﬁcity 43.5% 75% 80% 70% 71.4% 90% 80%
PPV 48% 92% 91.7% 80% 90% 95% 87.5%
NPV 50% 30% 44.4% 50% 29.4% 52.9% 61.5%
Diagnostic accuracy 48.8% 64% 71.4% 65.5% 62.1% 75.6% 75.8%
Best cut-oﬀ value 26 ng/mL 29 ng/mL
uNGAL, urinary neutrophil gelatinase associated lipocalin; PPV, positive predictive value; NPV, negative predictive value.
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days for the controls (P=NS).
Compared to the survivors, only at day 2 the non survivors
showed signiﬁcantly higher uNGAL values in both groups. At
day 1 uNGAL values were 40.8 ± 49.8(4–135) (ng/mL) in the
survivors, compared to 43.4 ± 26.4 (6–100) in the non survi-
vors (P=NS), but at day 2 uNGAL value was 14 ± 9 (2.9–
30) (ng/mL) in the survivors, compared to 52.5 ± 32.9 (2.5–
130) in those who died (P< 0.001), respectively.
Only at day 2, uNGAL values detected at days 1 and 2
could predict the mortality complicating acute kidney injury
and showed a good early prediction (area under curves were
0.65 and 0.86, and P< 0.05 and <0.001, respectively).
The best cutoff value was 29 ng/mL and 32 ng/mL at days 1
and 2, respectively (Table 6).
Discussion
Recent advances in the early stress response of renal tubule
cells to ischemic injury have provided several novel biomarkers
for AKI facilitating earlier diagnosis, proper management and
fewer complications improving the ﬁnal outcomes [10,21].
An ideal urinary biomarker in AKI should have several
characteristics, including reliable detection of AKI; being suf-
ﬁciently sensitive to detect early subclinical injury; reﬂecting
the location of kidney injury; reﬂecting time dependent
changes in the severity of injury, and being simple, cheap
and easy to be measured. It is generally accepted that no single
biomarker will perform sufﬁciently to stand alone as a diag-
nostic, injury severity, and prognostic marker [22].
The neutrophil gelatinase associated lipocalin (NGAL),
possibly is the most promising AKI biomarker in ICU settings
preceding a rise in serum creatinine by several hours to days[21]. It is easily detectable in the blood and urine soon after
ischemic or nephrotoxic kidney injury [23]. Both serum and
uNGAL (uNGAL) have been found to be reliable predictors
of AKI [11], but uNGAL is more sensitive and speciﬁc than
plasma-NGAL and is rapidly released after kidney injury [24].
Compared to the controls, in our study the uNGAL values
at day 1 were signiﬁcantly higher in the patients’ group
(52.2 ± 31.5 and 13.7 ± 9.2 respectively; P< 0.001) and at
day 2 (51.9 ± 32.7 and 15.7 ± 16.6, respectively; P< 0.001).
Compared to our controls, the conventional kidney function
tests showed signiﬁcantly higher values in the patients’ group
at all days except at day 1, but the values of uNGAL were sig-
niﬁcantly higher even at day 1.
This is in agreement with Mori et al., who studied cross sec-
tional ICU patients with AKI and found a >10-fold increase
in plasma-NGAL and a >100-fold increase in uNGAL com-
pared to their control group [25].
In our study, signiﬁcantly increased values of uNGAL at
days 1 and 2 were detected in the patients’ group, with reduc-
tion of the urine output (P< 0.05 and <0.001). We also
found good inverse correlations between UOP and uNGAL
at both days 1 and 2. AKI score showed also a good correla-
tion with uNGAL only at day 2; otherwise no correlation
could be detected between uNGAL and the other kidney func-
tion tests; including blood urea, serum creatinine and GFR.
Conversely Mori et al., found that both plasma and uN-
GAL correlated strongly with serum creatinine levels [25].
These ﬁndings were in disagreement with our study and may
be explained by the fact that, this study was conducted on pa-
tients with already established renal failure, while in our study,
the patients with circulatory shock were in a much earlier
phase. There are rapidly evolving and devolving stages of
AKI and variable kidney response to ﬂuid ± vasopressors
according to initial resuscitation management strategy [25].
Also, in a recent study conducted on 92 patients by
Wagener et al., it was shown that uNGAL/urine creatinine
ratio 3 h after liver transplantation is a very good marker of
AKI in all patients. The ROC curves of uNGAL/urine creati-
nine ratio to predict AKI were 0.8 (P< 0.001) at 3 h, and 0.64
(P< 0.05) at 18 h after reperfusion [24].
It is important to realize that, the temporal association of
urinary biomarker expression in relation to the rapidly evolv-
ing and devolving stages of AKI, including initiation, exten-
sion, maintenance, and recovery may have different
biomarker cutoff levels for detection of AKI [26].
To the best of our knowledge, our study is the ﬁrst to inves-
tigate whether uNGAL can predict AKI complicating circula-
tory shock (ischemic injury) in ICU patients. In our study, the
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at days 2, 3 and 4 showed a good early prediction of AKI, with
the best cutoff point of 26 ng/mL at day 1 and 29 ng/mL at day
2, respectively. The diagnostic accuracy in our study of
uNGAL test at day 1 was 64% and 71% for prediction of
AKI presented at days 2 and 3, respectively and of uNGAL
at day 2 was 76% and 76% for prediction of AKI presented
at days 3 and 4, respectively.
In a prospective study conducted by Mishra et al., they ob-
tained serial urine and serum samples from patients undergo-
ing cardiopulmonary bypass (CPB). They found that,
uNGAL concentrations >50 ng/mL reliably predicted AKI
in patients at only 2 h following CPB with 100% sensitivity
and 98% speciﬁcity [27]. Less optimistic results were reported
among patients undergoing cardiac surgery, uNGAL levels
were consistently higher at 1, 3, 18, and 24 h postoperatively
in patients who ultimately developed AKI with best cutoff of
213 ng/mL at 18 h postoperatively (with a sensitivity of 73%
and a speciﬁcity of 78%) [28]. Also another study conducted
by Koyner on adults undergoing elective cardiac surgery
showed that uNGAL predicted AKI following cardiac surgery
with a sensitivity of 66% and a speciﬁcity of 64% and a cutoff
at >550 ng/mL [29]. Han et al., reported that uNGAL can be
used from the ﬁrst day of injury as a reliable predictor of early
AKI in multi-trauma patients admitted to the ICU. The cutoff
point was >25 ng/mL for urinary NGAL with a sensitivity of
91% and a speciﬁcity of 95% in prediction of AKI [17].
Interestingly, these studies performed in adults undergo-
ing cardiac surgery showed that uNGAL was much less sen-
sitive and speciﬁc when predicting AKI after complex adult
cardiac surgery possibly due to the presence of more chronic
kidney disease and co-morbidities in these patients [24,30].
However, the majority of studies published thus far have in-
volved relatively small numbers of subjects from single cen-
ters, in which uNGAL appears to be most sensitive and
speciﬁc in homogeneous patient populations with predictable
forms of AKI [23]. But it is not surprising that the predic-
tive ability of uNGAL for AKI was less in the critically
ill population, since the cardiac surgery population repre-
sents a much more homogeneous group with a known onset
and mechanism of AKI [30].
The diagnostic characteristics of uNGAL are generally
compared against serum creatinine the existing gold standard
measure of AKI, although a creatinine-based diagnosis of
AKI is itself imperfect potentially contributing to apparent
limitations of new biomarkers and for evaluation of the accu-
racy and the clinical implications of a new test. So, a new bio-
marker with perfect sensitivity and speciﬁcity when compared
with serum creatinine would simply replicate the inaccuracies
of creatinine [22].
For the prediction of mortality complicating AKI, in our
study the values of uNGAL at day 2 could predict mortality
complicating AKI rather than at day 1 (area under curves were
0.65 and 0.86, and P< 0.05 and <0.001, respectively), with
the best cutoff value at 32 ng/mL. These results are in agree-
ment with Zappitelli et al., study which showed that the early
uNGAL levels were also predictive of duration of AKI in a
heterogeneous cohort of critically ill subjects [31]. Also, in an-
other study conducted on patients undergoing cardiac surgery;
they found that the 2 h uNGAL levels are highly correlated
with length of hospital stay and death [32].Limitations
The current study included a relatively small number of pa-
tients. It is acknowledged that our results, although of clear
clinical and statistical signiﬁcance, will need to be validated
in a larger population.
We used serum creatinine level as a comparator to assess
uNGAL performance and to deﬁne AKI, which is a bias. Since
serum creatinine based detection of AKI is considered some-
what inadequate sought to be replaced by new markers.
The current study design did not allow us to assess whether
the test would add to or improve clinical decision making; this
would need to be answered in a separate study once the cutoffs
are prospectively derived and validated.
Conclusion
A signiﬁcant increase in uNGAL was observed in ICU patients
following circulatory shock. Urinary-NGAL represents a good
early predictor biomarker of AKI following circulatory shock
and could predict the development of AKI 1–3 days earlier
than serum creatinine. Urinary-NGAL at second day follow-
ing shock could predict mortality complicating AKI.
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